This trial is evaluating whether MT-6402 will improve 4 primary outcomes, 3 secondary outcomes, and 8 other outcomes in patients with Oral Squamous Cell Carcinoma. Measurement will happen over the course of 28 days (Part 1).
This trial requires 138 total participants across 4 different treatment groups
This trial involves 4 different treatments. MT-6402 is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Oral squamous cell carcinoma can be diagnosed at any age, which makes it a lethal disease. However, patients do best when symptoms are first identified at an early stage. Oral squamous cell carcinoma is a common cancer that is treated with surgery, chemotherapy, or radiation therapy. Prognosis is determined by the stage of the cancer as well as by the treatment given. Patients may benefit from an alternative to conventional treatment in select cases.
Approximately 43,000 people will be diagnosed with oral SCC in the United States in 2002, a 20% increase over the previous year. The incidence of SCC of the vulva has increased at a comparable rate. These data highlight the need for cancer prevention and control programs.
Oral SCC has a cure rate of less than 1% if treated early. Patients diagnosed with early stage and well-differentiated oral SCC have an excellent chance of cure. Ondays, the cure rate falls to less than 35%, and the percentage of well-differentiated oral SCC that may be cured is around 25%. In the case of advanced oral SCC, cure at staging is very low and treatment is mostly palliative.
In the clinical setting of head and neck surgeon performing treatment of oral squamous cell carcinoma there are several signs that should alert the physician to the possibility of a malignant tumour. It is the absence of pain and redness on the palpation of a hard tumour that should be taken into account as these signs may be elicited by an underlying dental pathogenic process. It should be borne in mind that oral squamous cell carcinoma may be present solely on investigations, ie, dental radiographs, endo-labial videography, panendoscopy. Other imaging studies (for example CT scan, ultrasound, PET and MRI) are not routinely performed for head and neck tumours.
The term [head and neck cancer](https://www.withpower.com/clinical-trials/head-and-neck-cancer) is often used to refer to oropharyngeal cancer. Oral squamous cell carcinoma (OSCC) often includes the tongue, oropharynx and larynx and is the sixth most common cancer in the UK. This article covers head and neck and oral cancer. The word oropharongeal is a misnomer. The head and neck area is not confined just to the oral cavity and includes the parotid gland, the thyroid and salivary gland, the larynx and oesophagus, the pharynx, nasal cavity and paranasal sinuses and the upper respiratory tract.
The main risk factors for OSCC included smoking and a high alcohol consumption. The study supports an increased risk of oral cancer with heavy smoking and strengthens that there is a synergistic effect of heavy drinking and smoking on the development of OSCC.
Although the role of smoking is well documented, only a small number of people who smoke are diagnosed with OSCC. Further studies should concentrate on examining factors that confer protection against cigarette smoking in OSCC.
In a recent study, findings provides the safety of treatments given to patients ≥ 30 years old when performed < 7 days following the chemotherapy.
New developments in mt-6402, particularly concerning its application of chemotherapy through its ability to increase apoptosis in cancer cells, may permit more patients to benefit from this treatment in a clinical setting.
In conclusion, our findings indicate that neither genetic nor environmental factors are the sole cause of OSCC. Therefore, a complex interaction of both genetic-environmental factors is required for the development of OSCC. Since OSCC is associated with a familial occurrence, these findings warrant future studies in the families studied to identify familial susceptibility or protection as a contributing factor. Genetic markers of familial transmission may help to predict inherited susceptibility to develop oral potentially malign tumors.
The prognostic factors of the cancer and the extent of surgical resection were the major indicators for predicting the prognosis of OSCC. These two factors should be taken into consideration to make the treatment plans.
The majority of those who are eligible for a clinical trial do not complete the study. Reasons for non-completion include a change of medical management and deterioration of condition, with referral to specialists or palliative care as the last choice.